In 2017, the FDA approved regorafenib and nivolumab for the treatment of patients with hepatocellular carcinoma following prior sorafenib treatment, opening the door for an effective systemic second-line therapy in advanced disease. By contrast, the addition of sorafenib to transarterial chemoembolization with drug-eluting beads did not improve progression-free survival in the intermediate disease stage.
Subscribe to Journal
Get full journal access for 1 year
only $17.42 per issue
All prices are NET prices.
VAT will be added later in the checkout.
Rent or Buy article
Get time limited or full article access on ReadCube.
All prices are NET prices.
Bruix, J., Reig, M. & Sherman, M. Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology 150, 835–853 (2016).
Galle, P. R. et al. The treatment of intermediate stage tumours beyond TACE: from surgery to systemic therapy. J. Hepatol. 67, 173–183 (2017).
Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378–390 (2008).
Worns, M. A. & Galle, P. R. HCC therapies — lessons learned. Nat. Rev. Gastroenterol. Hepatol. 11, 447–452 (2014).
Bruix, J. et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 389, 56–66 (2017).
El-Khoueiry, A. B. et al. Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 389, 2492–2502 (2017).
Crocenzi, T. S. et al. Nivolumab (nivo) in sorafenib (sor)-naive and -experienced pts with advanced hepatocellular carcinoma: CheckMate 040 study [abstract]. J. Clin. Oncol. 35, 4013 (2017).
Lencioni, R. et al. Sorafenib or placebo plus TACE with doxorubicin-eluting beads for intermediate stage HCC: the SPACE trial. J. Hepatol. 64, 1090–1098 (2016).
Meyer, T. et al. Sorafenib in combination with transarterial chemoembolisation in patients with unresectable hepatocellular carcinoma (TACE 2): a randomised placebo-controlled, double-blind, phase 3 trial. Lancet Gastroenterol. Hepatol. 2, 565–575 (2017).
Finn, R. et al. Outcomes with sorafenib followed by regorafenib or placebo for hepatocellular carcinoma (HCC): results of the international, randomized phase 3 RESORCE trial (abstract). J. Clin. Oncol. 35, 344 (2017).
M.-A.W. has received consulting and lecture fees from Bayer and Bristol-Myers Squibb. P.R.G. has received consulting and lecture fees from AstraZeneca, Bayer, Bristol-Myers Squibb, Lilly, MSD/Merck, Roche, Sillajen, and Sirtex.
About this article
Cite this article
Wörns, M., Galle, P. Two large steps forward, one small step back. Nat Rev Gastroenterol Hepatol 15, 74–76 (2018). https://doi.org/10.1038/nrgastro.2017.174
Which choice of therapy when many are available? Current systemic therapies for advanced hepatocellular carcinoma
Health Science Reports (2020)
Circ_0001955 facilitates hepatocellular carcinoma (HCC) tumorigenesis by sponging miR-516a-5p to release TRAF6 and MAPK11
Cell Death & Disease (2019)
Advanced Drug Delivery Reviews (2019)
Metabolomic study of natrin-induced apoptosis in SMMC-7721 hepatocellular carcinoma cells by ultra-performance liquid chromatography-quadrupole/time-of-flight mass spectrometry
International Journal of Biological Macromolecules (2019)
Spatiotemporally Light-Activatable Platinum Nanocomplexes for Selective and Cooperative Cancer Therapy
ACS Nano (2019)